Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$52.09 USD
-1.68 (-3.12%)
Updated Sep 23, 2024 03:55 PM ET
After-Market: $52.10 +0.01 (0.02%) 5:32 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Cytokinetics, Incorporated falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -526.24 | -388.96 | -215.31 | -127.29 | -121.69 |
Depreciation/Amortization & Depletion | 11.89 | 5.81 | 2.28 | 1.83 | 1.29 |
Net Change from Assets/Liabilities | 3.09 | -24.70 | 8.46 | 89.12 | -0.34 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 96.93 | 108.33 | 62.06 | 45.29 | 29.83 |
Net Cash From Operating Activities | -414.33 | -299.52 | -142.52 | 8.94 | -90.91 |
Property & Equipment | -1.42 | -11.34 | -48.87 | -11.05 | -2.62 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 240.67 | -250.80 | -98.91 | -185.46 | -72.09 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 239.25 | -262.13 | -147.78 | -196.52 | -74.71 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 182.69 | 17.54 | 296.91 | 188.88 | 36.21 |
Issuance (Repayment) of Debt | -0.86 | 334.66 | 0.00 | 0.00 | 135.57 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 39.48 | 163.96 | 23.08 | 45.24 | -11.99 |
Net Cash from Financing Activities | 221.32 | 516.17 | 319.98 | 234.12 | 159.79 |
Effect of Exchange Rate Changes | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 46.22 | -45.48 | 29.68 | 46.55 | -5.82 |
Cash at Beginning of Period | 67.18 | 112.67 | 82.99 | 36.43 | 42.26 |
Cash at End of Period | 113.40 | 67.18 | 112.67 | 82.99 | 36.43 |
Diluted Net EPS | -5.45 | -4.33 | -2.80 | -1.97 | -2.11 |
Fiscal Year End for Cytokinetics, Incorporated falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -278.96 | -135.64 | -526.24 | -389.35 | -259.93 |
Depreciation/Amortization & Depletion | 4.74 | 2.33 | 11.89 | 5.56 | 3.70 |
Net Change from Assets/Liabilities | -15.93 | -25.70 | 3.09 | -41.79 | -43.27 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 61.34 | 29.51 | 96.93 | 85.29 | 55.40 |
Net Cash From Operating Activities | -228.82 | -129.51 | -414.33 | -340.30 | -244.09 |
Property & Equipment | -1.92 | 0.00 | -1.42 | -1.34 | -1.12 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -616.99 | 32.64 | 240.67 | 322.00 | 248.74 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -618.91 | 32.64 | 239.25 | 320.66 | 247.63 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 40.22 | 123.17 | 182.69 | 0.00 | 9.23 |
Issuance (Repayment) of Debt | -3.81 | -0.93 | -0.86 | -0.64 | -0.42 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 888.40 | -18.45 | 39.48 | 53.15 | -10.52 |
Net Cash from Financing Activities | 924.80 | 103.79 | 221.32 | 52.52 | -1.70 |
Effect of Exchange Rate Changes | 0.04 | 0.03 | -0.02 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 77.12 | 6.95 | 46.22 | 32.89 | 1.83 |
Cash at Beginning of Period | 113.40 | 113.40 | 67.18 | 67.18 | 67.18 |
Cash at End of Period | 190.52 | 120.35 | 113.40 | 100.07 | 69.01 |
Diluted Net EPS | -1.31 | -1.33 | -1.38 | -1.35 | -1.34 |